Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;27(3):471-82.
doi: 10.1016/j.cger.2011.03.010. Epub 2011 Jun 8.

Clinical trials on sarcopenia: methodological issues regarding phase 3 trials

Gabor Abellan van Kan  1 , Wm Cameron Chumlea, Sophie Gillette-Guyonet, Mathieu Houles, Charlotte Dupuy, Yves Rolland, Bruno Vellas
Affiliations
Review

Clinical trials on sarcopenia: methodological issues regarding phase 3 trials

Gabor Abellan van Kan et al. Clin Geriatr Med. 2011 Aug.

Abstract

Phase 3 trials estimate the effectiveness of an intervention to prevent, delay the onset of, or treat sarcopenia. Participants should have sarcopenia or present a sarcopenia risk profile. Control group should be characterized by the best standard of clinical care. This article further develops issues on sarcopenia definition, target population, primary and secondary end points, duration of the trials, muscle mass assessment, strength and physical performance assessment, and control of possible confounders. The challenges to conduct phase 3 trials in the elderly should not offset the opportunities for the development of new strategies to counteract sarcopenia and prevent late-life disability.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenberg IH. Summary comments. Am J Clin Nutr. 1989;50:1231–3.
    1. Abellan van Kan G. Epidemiology and consequences of sarcopenia. J Nutr Health Aging. 2009;13(8):708–12. - PubMed
    1. Pahor M, Cesari M. Designing phase IIB trials in sarcopenia. The best target population. J Nutr Health Aging. 2011 doi: 10.1007/s12603-011-0058-9. - DOI - PMC - PubMed
    1. Cruz-Jentoft A, Baeyens JP, Bauer J, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39:412–23. - PMC - PubMed
    1. Abellan van Kan G, Rolland Y, Andrieu S, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) task force. J Nutr Health Aging. 2009;13(10):881–9. - PubMed

Publication types